Back to Search
Start Over
Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives
- Source :
- Expert Opinion on Investigational Drugs. 27:787-801
- Publication Year :
- 2018
- Publisher :
- Informa UK Limited, 2018.
-
Abstract
- One-third of breast cancer (BC) cases worldwide occur in women aged 65 years and older, with 10 to 15% overexpressing the human epidermal growth factor receptor 2 (HER2). Although several HER2-targeted therapies have been developed, the lack of data regarding their use in older patients hampers evidence-based decision-making for this population.We review current evidence on the efficacy and safety of HER2-targeted therapies in older adults with BC, focusing on approved therapies such as trastuzumab, lapatinib, pertuzumab, ado-trastuzumab-emtansine, and neratinib. Additionally, we discuss drugs under development to target the HER2-receptor, and to overcome resistance to existing therapies. Finally, we highlight the cardiotoxicity of HER2-targeted drugs among older adults.Older adults are underrepresented in trials of HER2-targeted therapies in BC. We propose strategies to increase recruitment of older adults in clinical trials in order to increase the evidence base to treat this growing population.
- Subjects :
- Oncology
medicine.medical_specialty
Receptor, ErbB-2
Antineoplastic Agents
Breast Neoplasms
Lapatinib
03 medical and health sciences
0302 clinical medicine
Breast cancer
Trastuzumab
Internal medicine
HER2 Positive Breast Cancer
medicine
Humans
Pharmacology (medical)
Her2 receptor
Molecular Targeted Therapy
030212 general & internal medicine
skin and connective tissue diseases
Human Epidermal Growth Factor Receptor 2
Aged
Pharmacology
Clinical Trials as Topic
Cardiotoxicity
business.industry
Age Factors
General Medicine
medicine.disease
Drug Resistance, Neoplasm
Drug Design
030220 oncology & carcinogenesis
Female
Pertuzumab
business
medicine.drug
Subjects
Details
- ISSN :
- 17447658 and 13543784
- Volume :
- 27
- Database :
- OpenAIRE
- Journal :
- Expert Opinion on Investigational Drugs
- Accession number :
- edsair.doi.dedup.....0907ac1af3abe6efedc59ef8de892819